Sunday, December 28, 2008

Dynavax terminates hepatitis B vaccine license pact with Merck

Dynavax Technologies Corporation has terminated a global license and development collaboration agreement with Merck & Co, Inc for Heplisav, a phase-3 hepatitis B virus (HBV) vaccine. All rights to develop and commercialize Heplisav revert to Dynavax.

The details can be read here.

No comments: